Sign in

    John Wilkin • Craig-Hallum Capital Group LLC

    John Wilkin's questions to Neogenomics Inc (NEO) leadership

    John Wilkin's questions to Neogenomics Inc (NEO) leadership • Q2 2025

    Question

    John Wilkin of Craig-Hallum Capital Group LLC pointed out an apparent acceleration in core clinical volumes (excluding NGS and Pathline) and asked about the underlying drivers.

    Answer

    President & COO Warren Stone credited the strong performance in the core clinical business to the successful execution of their commercial strategy, including productivity gains from sales force investments and the ramp-up of new client wins from the previous quarter.

    Ask Fintool Equity Research AI

    John Wilkin's questions to Cerus Corp (CERS) leadership

    John Wilkin's questions to Cerus Corp (CERS) leadership • Q1 2025

    Question

    John Wilkin, on for Bill Bonello, requested more color on discussions with new geographies, the role of the next-gen illuminator as a catalyst in those talks, and any early interest in the new device. He also asked a follow-up question to identify the competent authority reviewing the new red blood cell submission.

    Answer

    Chief Operating Officer Vivek Jayaraman identified the Middle East (specifically Saudi Arabia) and Germany as key growth markets where the new INT-200 illuminator is a foundational device for expansion. He also noted progress with the company's joint venture in China. President and CEO Obi Greenman stated that while not final, the competent authority for the red blood cell review is expected to be Sul, the Czech authority.

    Ask Fintool Equity Research AI

    John Wilkin's questions to Cerus Corp (CERS) leadership • Q4 2024

    Question

    John Wilkin from Craig-Hallum Capital Group LLC questioned the slowdown in North American platelet growth during the quarter, asking if it was due to tougher year-over-year comparisons or other factors. He also inquired about other international geographies that are in the early stages of adopting the INTERCEPT system.

    Answer

    Executive Vivek Jayaraman attributed the platelet growth rate partly to comps and noted the company continues to capture share in North America, with underlying adoption trends remaining strong. For international growth, he highlighted progress in Germany, strong interest and investment in the Middle East (particularly Saudi Arabia), and the ongoing efforts in China as key geographies with significant growth potential over the next few years.

    Ask Fintool Equity Research AI